Scientific article
OA Policy
English

Complete remission with tyrosine kinase inhibitors in renal cell carcinoma

Published inJournal of clinical oncology, vol. 30, no. 5, p. 482-487
Publication date2012
Abstract

Complete remission (CR) is uncommon during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs), but it may occur in some patients. It remains a matter of debate whether therapy should be continued after CR.

Keywords
  • Adult
  • Aged
  • Antineoplastic Agents/therapeutic use
  • Benzenesulfonates/therapeutic use
  • Carcinoma, Renal Cell/drug therapy/secondary/surgery
  • Feasibility Studies
  • Female
  • Humans
  • Indoles/therapeutic use
  • Kidney Neoplasms/drug therapy/pathology/surgery
  • Male
  • Medical Records
  • Middle Aged
  • Molecular Targeted Therapy
  • Nephrectomy
  • Niacinamide/analogs & derivatives
  • Phenylurea Compounds
  • Protein Kinase Inhibitors/therapeutic use
  • Protein-Tyrosine Kinases/antagonists & inhibitors
  • Pyridines/therapeutic use
  • Pyrroles/therapeutic use
  • Questionnaires
  • Remission Induction
  • Retrospective Studies
  • Treatment Outcome
Citation (ISO format)
ALBIGES, Laurence et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. In: Journal of clinical oncology, 2012, vol. 30, n° 5, p. 482–487. doi: 10.1200/JCO.2011.37.2516
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
Journal ISSN0732-183X
698views
705downloads

Technical informations

Creation16/12/2014 08:38:00
First validation16/12/2014 08:38:00
Update time14/03/2023 23:28:19
Status update14/03/2023 23:28:19
Last indexation30/10/2024 22:31:27
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack